A New Frontier in Health Monitoring

If you or someone you care about lives with chronic kidney disease or is at risk of heart failure, you know the importance of keeping a close eye on potassium levels. This critical mineral can become a life-threatening issue when imbalanced. While technology has advanced leaps and bounds in glucose monitoring for diabetes, potassium monitoring has lagged behind—until now.

The Rise of Proton Intelligence

Enter Proton Intelligence, a pioneering startup based in Canada, stepping up to fill this crucial gap. Having recently secured $6.95 million in Seed financing led by SOSV, Proton is on the path to revolutionizing potassium monitoring with a continuous tracking device set to launch in 2025.

“No other technology currently offers this level of usability, accuracy, and clinical impact,” said Sahan Ranamukhaarachchi, CEO of Proton Intelligence.

— Sahan Ranamukhaarachchi

A Glimpse Into the Future

Proton’s innovative device will be a small sensor placed just beneath the skin, paired with a smartphone app to provide real-time potassium level updates. Imagine getting instant alerts if your levels become unsafe—empowering you to make informed lifestyle and medication choices. Not only does this innovation promise peace of mind for patients, but it also offers clinicians a comprehensive dashboard for monitoring trends and optimizing care strategies.

The Visionaries Behind Proton

The minds behind this groundbreaking innovation are CEO Sahan Ranamukhaarachchi and CSO Victor Cadarso. Both are seasoned experts in wearable biosensors, having honed their skills over a decade ago in Switzerland. Their journey has led them to establish Proton with a dual focus: a commercial headquarters in Canada and R&D operations in Melbourne.

Addressing a Global Challenge

The urgency of this innovation is underscored by the staggering statistic that 10% of the global population battles chronic kidney disease. The fear of potassium imbalance is real and palpable—often leaving patients anxious over something as simple as eating a banana or skipping a blood test.

• AliveCore: Tracks potassium via cardiac activity (raised $154.3 million)
• Alio: Focuses on dialysis patients (raised $46M)
• Renalyse: Uses finger-prick blood samples (raised €1 million)

A Promising Road Ahead

With significant backing from investors like We Venture Capital and Tenmile, Proton is poised for success. As Mohan S. Iyer from SOSV stated, “We are excited to support Proton Intelligence as they move into clinical validation.”

This innovative leap in healthcare technology not only promises to enhance patient outcomes but also holds the potential to alleviate the burden on healthcare systems globally. Stay tuned as Proton Intelligence continues its journey toward transforming how we monitor and manage potassium levels.